Ratings Dalmia Bharat Sugar and Industries Limited NSE India S.E.

Equities

Market Closed - NSE India S.E. Other stock markets 07:43:53 2024-06-25 EDT			5-day change	1st Jan Change
430.5 ^INR	+1.16%		+2.43%	+4.33%

05-14	India's Dalmia Bharat Sugar fourth-quarter profit falls on weak sales	RE
05-14	Dalmia Bharat Sugar and Industries Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024	CI

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach -100% by 2027.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Analysts covering this company mostly recommend stock overweighting or purchase.

For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last few months, analysts have been revising downwards their earnings forecast.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
DALMIA BHARAT SUGAR AND INDUSTRIES LIMITED	+4.33%	413M		-
SÜDZUCKER AG	-3.17%	3.01B		B+
SÃO MARTINHO S.A.	+12.42%	2.12B		C+
SHREE RENUKA SUGARS LIMITED	+9.25%	1.28B	-	C-
BALRAMPUR CHINI MILLS LIMITED	+7.37%	1.07B		B
TRIVENI ENGINEERING & INDUSTRIES LIMITED	+16.28%	1.05B		B-
ADECOAGRO S.A.	-15.68%	982M		B
SHANDONG BAILONG CHUANGYUAN BIO-TECH CO., LTD.	-5.26%	936M		-
MITSUI DM SUGAR HOLDINGS CO., LTD.	+14.44%	680M	-	-
SHANDONG SANYUAN BIOTECHNOLOGY CO.,LTD.	-16.27%	674M		-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality